The short version
What teams need to understand
- Pharmacovigilance systems must define clear delegation and backup arrangements for all roles.
- Responsibilities must be transferable without loss of control or compliance.
- Escalation pathways must be defined for safety issues and decision-making.
- Authority levels must be documented for each role and escalation tier.
- Backup coverage must ensure continuous availability of PV oversight.
- Inspection-ready evidence must demonstrate that delegation, escalation, and continuity are controlled and effective.
Regulatory expectation
What regulators expect
Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.
- Delegation must not result in loss of control or accountability.
- Backup arrangements must ensure continuous PV system operation.
- Escalation pathways must be clearly defined and followed.
- Authority for decision-making must be documented.
- Responsibility must remain clear even during delegation or absence.
Why it matters
What this means in practice
Inspectors assess whether pharmacovigilance systems maintain control through delegation, backup, and escalation processes. They review how responsibilities are transferred, how decisions are escalated, and how continuity of PV activities is maintained under all circumstances.
Questions this page answers
Inspection evidence
Evidence teams should be able to show
Delegation Records and Logs
- Formal delegation records for PV responsibilities
- Temporary role assignment documentation
- Defined delegation scope and limitations
- Approval of delegated responsibilities
Backup and Coverage Arrangements
- Deputy QPPV designation
- Backup roles for critical PV functions
- 24/7 availability coverage plans
- Handover documentation during absence
Escalation Procedures
- Defined escalation pathways for safety issues
- Escalation timelines for urgent cases
- Decision-making hierarchy documentation
- Communication protocols for escalation
Authority and Decision-Making Framework
- Defined authority levels for each role
- Decision-making rights for safety-critical issues
- Authority to escalate or override decisions
- Governance approval structures
Continuity and System Control Evidence
- Evidence of continuous PV system oversight
- Documentation showing no gaps during absence
- Case examples of delegation or escalation
- Governance records supporting decision-making
Regulatory Basis (Primary Sources)
- GVP Module I - requirement for continuous PV system control and defined responsibilities
- GVP Module VI - requirements for safety data management and escalation
- ICH E2D - expectations for maintaining continuous safety system operation
- MHRA GPvP guidance - requirements for availability and oversight of PV roles
- FDA pharmacovigilance guidance - accountability and continuity of safety oversight
Typical Inspection Questions (What Inspectors Ask)
- What happens if your QPPV is unavailable?
- How do you ensure continuous PV oversight?
- Who can make safety decisions in urgent situations?
- How are responsibilities delegated and documented?
- Show me how escalation is handled in your system.
Common failure patterns
What good looks like
- Clear delegation records and defined responsibility transfer.
- Effective backup and coverage for all critical PV roles.
- Defined escalation pathways for safety issues.
- Documented authority and decision-making framework.
- Continuous control and oversight of the PV system.
How teams operationalise it
- Define delegation processes within PV SOPs.
- Assign deputies and backup roles for critical positions.
- Establish escalation pathways and decision-making hierarchy.
- Document authority levels for all PV roles.
- Ensure continuity of PV operations during absence or change.
- Maintain records demonstrating delegation and escalation in practice.
From expectation to working control
Find the documentation that supports this work
Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.
Frequently asked questions
What is delegation in pharmacovigilance?
Delegation is the temporary or permanent transfer of responsibilities to another qualified individual while maintaining overall accountability.
Who is responsible when pharmacovigilance tasks are delegated?
Responsibility remains with the Marketing Authorisation Holder and relevant oversight roles such as the QPPV, even when tasks are delegated. Delegation does not transfer accountability, and the organisation must maintain control and oversight of all delegated activities.
How is backup coverage managed in pharmacovigilance?
Backup coverage is managed through defined deputy roles, handover procedures, and continuous availability arrangements.
What is escalation authority in pharmacovigilance?
Escalation authority defines who can make decisions and take action when safety issues arise.
Do inspectors review delegation and escalation processes?
Yes. Inspectors assess whether responsibilities are clearly defined, delegated appropriately, and supported by escalation pathways.
What happens if there is no backup coverage in PV?
Lack of backup coverage can result in inspection findings due to gaps in oversight and system control.
How do you ensure continuous PV system operation?
Continuous operation is ensured through delegation, backup coverage, defined escalation pathways, and governance oversight.
Source boundary
Regulatory sources
These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.
European Medicines Agency (EMA)
Guideline on good pharmacovigilance practices (GVP) - Module I
View sourceGuideline on good pharmacovigilance practices (GVP) - Module VI
View source
FDA
Postmarketing Safety Reporting
View source
ICH
Post-Approval Safety Data Management (E2D)
View source
MHRA
Good Pharmacovigilance Practice (GPvP)
View source